Mycobacterium tuberculosis sensitivity to 1-(4-Methylimidazol-5-oyl)-4-(4-dimethyloaminophenyl)thiosemicarbazide and obtainment the resistant mutants by chemical mutation. Mycobacterium tuberculosis H37Rv

As part of global efforts to develop an efficient anti-tuberculosis drug, our group is focused on the development of new thiosemicarbazide based compounds as potential anti-Mtb agents. In view of the importance of the thiosemicarbazide moiety, we investigate the anti-Mtb activity of new imidazole-thiosemicarbazide derivatives. The Mtb cultures were preincubated in the sub-inhibitory concentration of compound (0.1xMIC90) by three passages before plating. Then resistant mutants to 1-(4-Methylimidazol-5-oyl)-4-(4-dimethyloaminophenyl)thiosemicarbazide were selected on 7H10/OADC solid media supplemented with 3xMIC90 (97.8 ug/mL) of compound. In this project, we have evaluated the possible effect of compound on Mtb and compare frequency and profile of mutations accumulated in wild type and resistant mutants Mtb strains growing in the presence of 1-(4-Methylimidazol-5-oyl)-4-(4-dimethyloaminophenyl)thiosemicarbazide.